{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloid+Cardiomyopathy&page=2",
    "query": {
      "condition": "Transthyretin Amyloid Cardiomyopathy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloid+Cardiomyopathy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T12:19:21.277Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06128629",
      "title": "MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "NTLA-2001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Intellia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 1200,
      "start_date": "2023-12-13",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06128629"
    },
    {
      "nct_id": "NCT01855360",
      "title": "Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyloidosis; Heart (Manifestation)",
        "Senile Cardiac Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Tauroursodeoxycholic Acid and Doxycycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-06",
      "completion_date": "2015-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01855360"
    },
    {
      "nct_id": "NCT06073574",
      "title": "CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)"
      ],
      "interventions": [
        {
          "name": "Cardiac MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-03-31",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06073574"
    },
    {
      "nct_id": "NCT06393465",
      "title": "Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)"
      ],
      "interventions": [
        {
          "name": "Tafamidis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-06-15",
      "completion_date": "2026-04-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06393465"
    },
    {
      "nct_id": "NCT03812172",
      "title": "Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyloid Cardiomyopathy, Transthyretin-Related"
      ],
      "interventions": [
        {
          "name": "99mTc-PYP or 99m Tc-HDP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mathew S. Maurer, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 646,
      "start_date": "2019-05-15",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03812172"
    },
    {
      "nct_id": "NCT03294707",
      "title": "Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyloid Cardiomyopathy, Transthyretin-Related"
      ],
      "interventions": [
        {
          "name": "AG10 oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eidos Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2017-09-11",
      "completion_date": "2018-05-18",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03294707"
    },
    {
      "nct_id": "NCT07591038",
      "title": "PET/CT Imaging in Carriers of TTR Mutations",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ATTR",
        "ATTR Gene Mutation",
        "Cardiomyopathy",
        "Transthyretin Mediated Amyloidosis (ATTR)"
      ],
      "interventions": [
        {
          "name": "Iodine-124 Evuzamitide (I-124E)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-08-01",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07591038"
    },
    {
      "nct_id": "NCT03923920",
      "title": "Screening for Systemic Amyloidosis Via the Ligamentum Flavum",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyloid",
        "Amyloidosis",
        "Spinal Stenosis",
        "Transthyretin Amyloidosis",
        "Primary Amyloidosis of Light Chain Type"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2019-05-01",
      "completion_date": "2021-12-02",
      "has_results": false,
      "last_update_posted_date": "2021-12-22",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03923920"
    },
    {
      "nct_id": "NCT03759379",
      "title": "HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyloidosis, Hereditary",
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Patisiran",
          "type": "DRUG"
        },
        {
          "name": "Vutrisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 164,
      "start_date": "2019-02-14",
      "completion_date": "2025-11-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 15,
      "location_summary": "La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03759379"
    },
    {
      "nct_id": "NCT01994889",
      "title": "Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin (TTR) Amyloid Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Tafamidis",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 441,
      "start_date": "2013-12-09",
      "completion_date": "2018-02-07",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-06-10T12:19:21.277Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01994889"
    }
  ]
}